Hibiscus sabdariffa L., roselle calyx, from ethnobotany to pharmacology

Journal of Experimental Pharmacology

Volumn 4, Issue 1, 2012, Pages 25-39

  Carvajal Zarrabal, Octavio ^a   María, Dulce ^d   Barradas Dermitz, ^b   Orta Flores, Zaida ^b   Margaret, Patricia ^d   Hayward Jones, ^a   Nolasco Hipólito, Cirilo ^c   Aguilar Uscanga, M Guadalupe ^b   Miranda Medina, Anilú ^b   Bujang, Kopli Bin ^c  

^a UNIVERSIDAD VERACRUZANA   (Mexico)

^b INSTITUTO TECNOLÓGICO DE VERACRUZ   (Mexico)

^c UNIVERSITI MALAYSIA SARAWAK   (Malaysia)

^d NONE

Author keywords

Anthocyanins; Antihypertensive; Apoptosis; Lipid metabolism; Phenolic; Polyphenolic compounds; Safe effective herbal therapeutic product

Indexed keywords

AFLATOXIN; ANTHOCYANIDIN; ANTHOCYANIN; ASCORBIC ACID; BETA CAROTENE; CALCIUM; CITRIC ACID; CYANIDIN 3 GLUCOSIDE; DELPHINIDIN; EUGENOL; HIBISCUS SABDARIFFA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; MALIC ACID; MALVIN; OXALIC ACID; PLANT MEDICINAL PRODUCT; POLYPHENOL DERIVATIVE; PROTOCATECHUIC ACID; QUERCETIN; RIBOFLAVIN; RUTOSIDE; SOLVENT; TARTARIC ACID; THIAMINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIHYPERTENSIVE ACTIVITY; APOPTOSIS; BIBLIOGRAPHIC DATABASE; CHEMICAL COMPOSITION; CHRONOLOGY; COMMUNITY; COMPLEX FORMATION; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ETHNOBOTANY; ETHNOPHARMACOLOGY; EXERCISE; HIBISCUS SABDARIFFA; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; LIPID METABOLISM; MEDLINE; NONHUMAN; PHYTOCHEMISTRY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; REVIEW; SCIENTIFIC LITERATURE; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84891413797     PISSN: None     EISSN: 11791454     Source Type: Journal    
DOI: 10.2147/JEP.S27974     Document Type: Review

References (64)

1. El-Saadany SS, Sitohy MZ, Labib SM, El-Massry RA. Biochemical dynamics and hypocholesterolemic action of Hibiscus sabdariffa (Karkade). Nahrung. 1991;35:567-576.
2. Wilson EK. Scripps Research Institute thrives at interface of chemistry and biology. Chem Eng News. 1996;174:39-44.
3. Onyenekwe PC, Ajani EO, Ameh DA, et al. Antihypertensive effect of roselle (Hibiscus sabdariffa) calyx infusion in spontaneously hypertensive rats and a comparison of its toxicity with that in Wistar rats. Cell Biochem Funct. 1999;17:199-206.
4. Haji-Faraji MH, Haji-Tarkhani AH. The effect of sour tea (Hibiscus sabdariffa) on essential hypertension. J Ethnopharmacol. 1999;65: 231-236.
5. Wang CJ, Wang JM, Lin WL, et al. Protective effect of Hibiscus anthocyanins against ter-butyl hydroperoxide-induced hepatic toxicity in rats. Food Chem Toxicol. 2000;38:411-416.
6. Wang CJ. Method to counter oxidation LDL, decrease triacylglyceride or cholesterol and inhibit atherosclerosis using Hibiscus sabdariffa extract. United States Patient Application No 0096021. 2003 May 22.
7. Ross IA. Medicinal plants of the World. Vol I. Totawa, NJ: Humana Press; 2003.
8. Chen CC, Hsu JD, Wang SF, et al. Hibiscus sabdariffa extract inhibits the development of atherosclerosis in cholesterol-fed rabbits. J Agric Food Chem. 2003;51:5472-5477.
9. Chen CC, Chou FP, Ho YC, et al. Inhibitory effects of Hibiscus sabdariffa L extract on low-density lipoprotein oxidation and antihyperlipidemia in fructose-fed and cholesterol-fed rats. J Sci Food Agric. 2004;84:1989-1996.
10. Odigie IP, Ettarh RR, Adigun SA. Chronic administration of aqueous extract of Hibiscus sabdariffa attenuates hypertension and reverses cardiac hypertrophy in 2K-1 hypertensive rats. J Ethnopharmacol. 2003;86:181-185.
11. Herrera-Arellano A, Flores-Romero S, Chávez-Soto MA, et al. Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild moderate hypertension: a controlled and randomized clinical trial. Phytomed. 2004;11:375-382.
12. Herrera-Arellano A, Miranda-Sánchez J, Avila-Castro P, et al. Clinical effects produced by a standardized herbal medical product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. Planta Med. 2007;73:6-12.
13. Carvajal-Zarrabal O, Waliszewski SM, Barradas-Dermitz DM, et al. The consumption of Hibiscus sabdariffa dried calyx ethanolic extract reduced lipid profile in rats. Plant Foods Hum Nutr. 2005;60:153-159.
14. Carvajal-Zarrabal O, Hayward-Jones PM, Orta-Flores Z, et al. Effect of Hibiscus sabdariffa dried calyx ethanolic extract on fat absorptionexcretion and body weight implication in rats. J Biomed Biotechnol. 2009;2009:394592.
15. Hirunpanich V, Utaipat A, Morales NP, et al. Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of Hibiscus sabdariffa L. in hypercholesterolemic rats. J Ethnopharmacol. 2006;103:252-260.
16. Chang YC, Huang KX, Huang AC, et al. Hibiscus anthocyanin-rich extract inhibited LDL oxidation and oxLDL-mediated macrophages apoptosis. Food Chem Toxicol. 2006;44:1015-1023.
17. Lin HH, Huang HP, Huang CC, et al. Hibiscus polyphenol-rich extract induces apoptosis in human gastric carcinoma cells via p53 phosphorylation and p38 MAPK/FasL cascade pathway. Mol Carcin. 2005;43:86-99.
18. Lin HH, Chen JH, Huang CC, et al. Apoptotic effect of 3,4-dihydroxybenzoic acid on human gastric carcinoma cells involving JNK/p38 MAPK signaling activation. Int. J Cancer. 2007;120: 2306-2316.
19. Lin HH, Chen JH, Kuo WH, et al. Chemopreventive properties of Hibiscus sabdariffa L. on human gastric carcinoma cells through apoptosis induction and JNK/p38 MAPK signaling activation. Chem Biol Interact. 2007;165:59-75.
20. Lin TL, Lin HH, Chen CC, et al. Hibiscus sabdariffa extract reduces serum cholesterol in men and women. Nut Res. 2007;2:140-145.
21. Ajay M, Chai HJ, Mustafa AM, et al. Mechanisms of the anti-hypertensive effect of Hibiscus sabdariffa L. calyces. J Ethnopharmacol. 2007;109:338-393.
22. Farnsworth NR. The role of ethnopharmacology in drug development. In: Chadwick DJ, Marsh J, editors. Ciba Foundation 154-Bioactive Compounds from Plants. Novartis Foundation Symposia; 1990. September 28, 2007.
23. Ali BH, Naser AWN, Blunden G. Phytochemical, pharmacological and toxicological aspects of Hibiscus sabdariffa L.: A Review. Phytother Res. 2005;19:369-375.
24. Gomes ME, da Costa HR, Moreira RR, et al. Pharmacological evidences of the extracts and secondary metabolites from plants of the genus Hibiscus. Food Chem. 2010;118:1-10.
25. Nnam NM, y Onyeke NG. Chemical compositions of two varieties of sorrel (Hibiscus sabdariffa L.), calyces and the drinks made from them. Plant Foods Hum Nutr. 2003;58:1-7.
26. Ojokoh AO. Roselle (Hibiscus sabdariffa) calyx diet and histopathological changes in liver of albino rats. Pak J Nutr. 2006;5:110-113.
27. Adanlawo IG, Ajibade VA. Nutritive value of the two varieties of roselle (Hibiscus sabdariffa) calyces soaked with wood ash. Pak J Nutr. 2006;5:555-557.
28. Falade OS, Otemuyiwa IO, Oladipo A, et al. The chemical composition and membrane stability activity of some herbs used in local therapy for anemia. J Ethnopharmacol. 2005;102:15-22.
29. Bear FE, Toth SJ, Prince AL. Variation in mineral composition of vegetables. Soil Sc Soc Am Proc. 1948;13:380-384.
30. Lipids Online Educational Resources in Atherosclerosis [homepage on the Internet]. Available from: http://www.lipidsonline.org/clinicalcases/mixed- hyperlipidemia/. Accessed September 28, 2010.
31. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, et al. Characteristics of mixed hyperlipidemia cases in a population-based study: Results from the Mexican National Survey of Chronic Diseases. Salud Pública de México. 2002;44:546-553.
32. Cullen P, Schulte H, Assmann G. The Münster Heart Study (PROCAM). Circulation. 1997;96:2128-2136.
33. Law MR, Wald NJ, Wu T, et al. Systematic underestimation of association between serum cholesterol concentration and ischemic heart disease in observational studies: data from the BUPA Study. BMJ. 1994;308:363-366.
34. Neaton JD, Blackburn H, Jacobs D, et al. For the multiple risk factor Intervention trial research group. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Arch Intern Med. 1992;152:1490-1500.
35. Pekkanen J, Nissinen A, Punsar S, et al. Short- and long-term association of serum cholesterol with mortality: the 25-year follow-up of the Finnish cohorts of the seven countries study. Am J Epidemiol. 1992;135:1251-1258.
36. Assmann G, Schulte H. Role of triacylglycerides in coronary artery disease: lessons from the prospective cardiovascular Munster study. Am J Cardiol. 1992;70:10H-13H.
37. Wilson PFW, Abbott RD, Castelli WP. High-density lipoprotein cholesterol and mortality: the Framingham Study. Arteriosclerosis. 1988;8:737-741.
38. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA. 1987;257: 2176-2180.
39. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and treatment of high blood cholesterol in adults. Third report of NCEP expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143-3421.
40. Lee MJ, Cho FP, Tseng TH, et al. Hibiscus protocatechuic acid or esculetin can inhibit oxidative LDL induced by copper ion or nitric oxide donor. J Agric Food Chem. 2002;50:2130-2136.
41. Mohamed Essa M, Subramanian P, Manivasagam T, et al. Protective influence of Hibiscus sabdariffa, an edible medicinal plant, on tissue lipid peroxidation and antioxidant status in hyperammonemic rats. African Journal of Traditional, Complementary and Alternative Medicine. 2006;3:10-21.
42. Yang MY, Peng CH, Chan KC, et al. The hypolipidemic effect of Hibiscus sabdariffa polyphenols via inhibiting lipogenesis and promoting hepatic lipid clearance. J Agr Food Chem. 2010;58:850-859.
43. Velázquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A, et al. Arterial hypertension in Mexico: Results of the National Health Survey (ENSA) 2000 [Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000]. Arch Card Méx. 2002;72:71-84. [Spanish.]
44. Ali MB, Salih WM, Mohamed AH, et al. Investigation of the antispasmodic potential of Hibiscus sabdariffa calyces. J Ethnopharmacol. 1991;31:249-257.
45. Bennet JC, Plum F, Wyngaarden JB. Cecil Textbook of Medicine, 20th ed. Philadelphia, PA: Saunders; 1996.
46. Tiamjan R. Hypotensive activity of Hibiscus sabdariffa Linn. MSc Thesis. Chang Mai, Thailand: Department of Pharmacology, Chiang Mai University; 1999.
47. Mojiminiyi FBO, Dikko M, Muhammad BY, et al. Antihypertensive effect of an aqueous extract of the calyx of Hibiscus sabdariffa. Fitoterapia. 2007;78:292-297.
48. Mozaffari-Khosravi H, Jalali-Khanabadi B-A, Afkhami-Ardekani M, et al. The effects of sour tea (Hibiscus sabdariffa) on hypertension in patients with type II diabetes. J Hum Hypertens. 2009;23:48-54.
49. McKay DL, Chen CY, Saltzman E, et al. Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. J Nutr. 2010;140:298-303.
50. Ojeda D, Jiménez-Ferrer E, Zamilpa A, et al. Inhibition of angiotensin converting enzyme (ACE) activity by the anthocyanins delphinidin- and cyanidin- 3-O-sambubiosides from Hibiscus sabdariffa. J Ethnopharmacol. 2010;127:7-10.
51. Kameda K, Takaku T, Okuda H, et al. Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987;50:680-683.
52. Loizzo MR, Said A, Tundis R, et al. Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from Allanthus excelsa (Roxb) (Simaroubaceae). Phytother Res. 2007;21:32-36.
53. Chen CH, Lin JY, Lin, CN, et al. Inhibition of angiotensin-I-converting enzyme by tetrahydroxyxanthones isolated from Tripterosperum lanceolatum. J Nat Prod. 1992;55:691-695.
54. Spowage BM, Bruce CL, Hirst JD. Interpretable correlation descriptors for quantitative structure-activity relationships. J Cheminform. 2009;1:22.
55. Wahabi HA, Alansary LA, Al-Sabban AH, et al. The effectiveness of Hibiscus sabdariffa in the treatment of hypertension: A systematic review. Phytomed. 2010;17:83-86.
56. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
57. Nijhawan D, Honarpour N, Wang X. Apoptosis in neural development and disease. Annu Rev Neurosci. 2000;23:73-87.
58. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
59. Singh N. Apoptosis in health and disease and modulation of apoptosis for therapy: an overview. Indian J Clin Biochem. 2007;22(2):6-16.
60. Goillot E, Raingeaud J, Ranger A, et al. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci U S A. 1997;94:3302-3307.
61. Cowan KJ, Storey KB. Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J Exp Biol. 2003;206:1107-1115.
62. Tseng TH, Kao TW, Chu CY, et al. Induction of apoptosis by Hibiscus protocatechuic acid in human leukemia cells via reduction of retinoblastoma (RB) phosphorylation and Bcl-2 expression. Biochem Pharmacol. 2000;60:307-315.
63. Kampa M, Alexaki VI, Notas G, et al. Antiproliferative and apoptotic effects of selective phenolic acids on TD47 human breast cancer cells: potential mechanisms of action. Breast Cancer Res. 2004;6:63-74.
64. Guan S, Jiang B, Bao YM, et al. Protocatechuic acid suppresses MPP+-induced mitochondrial dysfunction and apoptotic cell death in PC12 cells. Food Chem Toxicol. 2006;44:1659-1666.